Further, completion of several ongoing clinical trials, including, EMPEROR-Reduced, EMPEROR-Preserved, DAPA-HF, DAPA-DKD and CREDENCE, will shed insights into the CV and renoprotective effects of SGLT2 inhibitors [68]. The gene discussed is SLC5A2; the disease is diabetic kidney disease.